Abstract Background Lenacapavir (LEN) is a first-in-class, long-acting HIV-1 capsid inhibitor, approved for the treatment of heavily treatment-experienced (HTE) people with HIV (PWH) with multidrug resistance (MDR). To date, few data are available on resistance profiles in real life. Methods Paired plasma and PBMC samp...
Maria Mercedes Santoro, D. Spalletta, V. Spagnuolo et al.· Journal of Antimicrobial Che...· 0 citations
OBJECTIVES
To determine the clinical significance of circulating plasma SARS-CoV-2 RNA across acute COVID-19 and post-COVID condition (PCC) by investigating prevalence, determinants, and kinetics in a large longitudinal cohort, accounting for hospitalization and vaccination.
METHODS
We consecutively enrolled individu...
Roberta Rovito, L. Terracciano, Giuseppe De Pinto et al.· Clinical Microbiology and In...· 0 citations
Findings highlight variant-specific limitations of anti-Spike IgG as a universal marker of protection and support the need for integrated serological and virological assessment to guide antiviral and monoclonal antibody strategies in vulnerable populations.
Matteo Domenico Marsiglia, Roberta Rovito, A. Amendola et al.· Journal of microbiology, imm...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.